Amgen (AMGN) Market Capitalization, Earnings, Price, Holders
Symbol: AMGN Rank: #97 Price: $230.5(0.51895%)

Market Cap: $126.7B($657.7M) Industry: Drug Manufacturers General Sector: Healthcare Country: United States Insiders: 0.209% Institutions: 79.929%
Amgen Inc. Technicals

52 Week High: $292.07

52 Week Low: $219.11

50 Day MA: $253.68

200 Day MA: $252.7

52 Week Trading Range


Low: $219.11

High: $292.07

Daily Trading Range


Low: $229.15

High: $232.02

Market capitalization history for Amgen (AMGN) in USD

As of November 2023, Amgen (AMGN) has a market cap of $126.7 billion. Our data points out that AMGN is ranked #97 in the world. A company's market capitalization is the present value of all of its outstanding shares, and it is commonly used to give a sense of how much the stock of a company would be worth at today's exchange rates. AMGN's market cap is 0.518949% up from the last trading day.

AMGN Statistics

Market Cap
Revenue TTM
Gross Profit TTM
Operating Margin TTM
Shares Outstanding
Shares Float
Trading Volume
P/E Ratio
PEG Ratio
Revenue Per Share
Dividend Per Share
Dividend Yield
Quote Type
Leaf logo
CDP Climate Change Score (AMGN)

Latest News

Amgen (AMGN) Shares Stats
Amgen (AMGN) Valuation
Trailing P/E $19.4967
Forward P/E $14.9477
Price Sales TTM $5.4945
Price Book MRQ $39.6029
Enterprise Value $171,895,330,122
Enterprise Value Revenue $6.5285
Enterprise Value Ebitda $13.848
Amgen Inc. Details

Address: One Amgen Center Drive

City: Thousand Oaks

Zip: 91320-1799

Phone: 805 447 1000


IPO Date: 1983-06-17

CEO: Robert A. Bradway

Employees: 24,200

What is AMGN about?

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.